Health Technology and Social Research
https://healthsocres.com

Wearable Data Sharing and Equity Monitoring for Privacy Concern in Chronic Illness Groups

Chi-Wai Yiu*

Department of Social Science, School of Humanities and Social Science, Hang Seng University of Hong Kong, Hong Kong, Hong Kong SAR, China

Corresponding author: chi.w.yiu@hsu.edu.hk

Abstract

The rapid proliferation of wearable health technologies has revolutionized chronic illness management by enabling continuous, real-time monitoring of physiological signals. However, the collection and transmission of highly sensitive health data generate profound privacy concerns among patient populations. This study systematically investigates the factors shaping privacy concerns in wearable data sharing, with a specific focus on the role of equity monitoring in chronic illness groups. Integrating privacy calculus theory with socioeconomic equity frameworks, we establish a comprehensive model to analyze how perceived benefits, perceived risks, trust in healthcare institutions, and digital equity impact patients' willingness to share data. Through a survey of chronic illness patients, we examine the structural relationships between these variables. The empirical findings indicate that while health benefits strongly motivate data sharing, privacy concerns remain a substantial barrier, particularly exacerbated by perceived inequities in data access and algorithmic bias. Moreover, equity monitoring acts as a critical moderator that can mitigate privacy anxieties when patients perceive that data collection leads to fairer healthcare distribution. This research contributes to health informatics literature by providing a nuanced understanding of how privacy and equity intersect in digital health ecosystems, offering actionable insights for clinicians, developers, and policymakers aiming to design inclusive and secure health-monitoring interventions.

Keywords: Wearable Health Technology; Privacy Concern; Health Equity; Chronic Illness; Wearable Data Sharing

1. Introduction

1.1 Background and Context

The global healthcare landscape is experiencing an unprecedented epidemiological transition characterized by the rising prevalence of chronic conditions, such as cardiovascular diseases, type 2 diabetes, chronic obstructive pulmonary disease, and chronic kidney disease. Managing these conditions requires a fundamental shift from traditional, episodic clinical encounters to continuous, proactive, and personalized care paradigms [1]. In this context, consumer-grade and medical-grade wearable health devices have emerged as transformative tools. These devices, which include smartwatches, continuous glucose monitors, and wearable electrocardiogram patches, offer the capability to collect high-fidelity, longitudinal physiological telemetry, including heart rate variability, blood glucose fluctuations, oxygen saturation, and physical activity patterns [2]. By transmitting this continuous stream of data to clinical teams, wearable technologies facilitate early detection of acute exacerbations, enable precise adjustments to therapeutic regimens, and empower patients to actively engage in self-management.

Despite these clinical promises, the widespread deployment of wearable health devices faces significant socio-technical bottlenecks, chief among which is the multi-dimensional challenge of privacy. Unlike conventional medical data generated within the secure boundaries of hospital networks and protected by rigorous regulatory frameworks, wearable data are frequently transmitted across public telecommunications infrastructure, processed by third-party commercial applications, and stored in distributed cloud environments [3]. This decentralized data lifecycle exposes patients to a myriad of privacy risks, ranging from malicious cyberattacks and data breaches to insidious secondary uses, such as commercial behavioral profiling, insurance discrimination, and employment prejudice. For chronic illness patients, who must manage their conditions over several decades, the cumulative risk of exposing sensitive somatic data represents a profound psychological and material threat.

Furthermore, the integration of wearable technology into public health tracking and clinical workflows raises significant questions regarding socioeconomic and health equity [4]. While continuous monitoring has the potential to bridge gaps in clinical access, it also threatens to exacerbate existing health disparities if implemented without explicit equity safeguards. Patients from marginalized racial, ethnic, or socioeconomic backgrounds often face systemic barriers to digital health adoption, including limited digital literacy, lack of broadband connectivity, and the financial burden of purchasing wearable devices. When healthcare systems utilize wearable data to allocate resources or evaluate clinical outcomes, populations unable to participate in these digital monitoring ecosystems may experience further exclusion and systemic neglect [5]. Consequently, equity monitoring, which entails the systemic auditing of how digital health technologies are distributed and how their algorithmic models affect diverse patient subgroups, has become a core ethical mandate in contemporary medical informatics [6].

1.2 Research Objectives and Contributions

This study addresses a critical gap in the existing literature by exploring the complex intersection of patient privacy concerns, wearable data-sharing behaviors, and equity monitoring within chronic illness cohorts. While previous research has applied the privacy calculus model to examine health data disclosure, these inquiries have predominantly treated the individual as an isolated actor making rational utility trade-offs, largely overlooking the socio-structural dimensions of health equity and institutional justice. In chronic care ecosystems, privacy decisions are not made in a vacuum; rather, they are deeply shaped by the patient's trust in the healthcare system and their perception of whether the benefits and burdens of digital tracking are distributed fairly across society.

Therefore, the primary objective of this investigation is to establish and empirically validate a structural model that explains how chronic illness patients evaluate the trade-offs of wearable data sharing under varying perceptions of health equity and institutional monitoring. Specifically, we investigate how perceived data equity and the presence of active equity monitoring frameworks influence patients' cognitive assessment of privacy risks and their subsequent willingness to disclose wearable telemetry to healthcare providers and research institutions.

By achieving these objectives, this research makes three principal contributions to the fields of health informatics and public health policy. First, it expands the traditional privacy calculus framework by integrating systemic equity dimensions, thereby offering a more holistic explanation of data-sharing dynamics in vulnerable populations. Second, it provides empirical evidence regarding how chronic illness patients perceive the dual-edged sword of equity monitoring, illustrating that structured oversight of algorithm fairness can serve as an institutional trust-building mechanism that alleviates privacy concerns. Finally, it offers practical, evidence-based guidelines for clinical administrators and digital health developers to design wearable monitoring architectures that are not only technologically robust and secure but also ethically aligned with the principles of health equity and social justice.

2. Theoretical Framework and Literature Review

2.1 Wearable Technology in Chronic Disease Management

The integration of wearable devices into clinical practice marks a departure from traditional symptom-reactive medicine toward a preventative, data-driven approach. Chronic diseases are inherently dynamic, with physiological parameters fluctuating in response to diet, medication, environmental stressors, and lifestyle changes [7]. Traditional clinical evaluations, restricted to intermittent visits, offer only static snapshots of a patient's health, often failing to capture transient pathological events such as silent arrhythmias, nocturnal hypoglycemic episodes, or early signs of respiratory distress. Wearable technologies mitigate this limitation by providing continuous, ambient monitoring, thereby establishing a high-frequency digital biomarker profile that reflects the real-time health status of the individual [8].

In diabetes management, for instance, continuous glucose monitoring systems have replaced painful, intermittent finger-prick tests, providing real-time interstitial glucose readings every few minutes. These systems not only alert patients to impending hyper- or hypoglycemic states but also transmit trend data to clinicians, enabling precise, personalized insulin titration. Similarly, in cardiovascular disease management, wearable photoplethysmography and electrocardiogram sensors enable the passive detection of atrial fibrillation, allowing for timely pharmacological interventions that significantly reduce the risk of ischemic stroke. In respiratory conditions such as chronic obstructive pulmonary disease, continuous tracking of blood oxygen saturation and respiratory rate can predict acute exacerbations several days before clinical symptoms manifest, allowing for preemptive outpatient care that prevents expensive and traumatic emergency hospitalizations.

However, the continuous nature of wearable monitoring also implies that the volume, velocity, and variety of the collected data are unprecedented. These data streams do not merely contain isolated clinical metrics; they are intrinsically linked to the patient's daily life, capturing patterns of movement, sleep quality, geolocations, and social interactions. Consequently, the boundary between clinical telemetry and personal lifestyle data becomes increasingly blurred. This integration of the private sphere into the clinical monitoring apparatus underpins the escalating concerns regarding patient privacy and data governance in modern healthcare.

2.2 Privacy Calculus Theory and Health Data Sharing

To systematically analyze how patients navigate the disclosure of highly sensitive physiological data, researchers frequently employ the Privacy Calculus Theory [9]. Originating from social exchange theory, this framework posits that individuals do not make privacy decisions based solely on irrational fears or absolute desires for secrecy. Instead, they act as rational agents who perform a cognitive, cost-benefit calculus, weighing the expected benefits of disclosing personal information against the potential risks associated with its exposure [10]. When the perceived benefits of disclosure outweigh the perceived risks, individuals are likely to share their data; conversely, if the risks are perceived as dominant, disclosure avoidance behaviors manifest.

In the context of wearable technology and chronic illness, the utility side of the calculus is often substantial and highly tangible. The benefits include receiving more accurate diagnoses, experiencing improved health outcomes, gaining peace of mind through continuous clinical oversight, and participating in medical research that could benefit future generations of patients. For individuals suffering from debilitating or life-threatening chronic conditions, these health benefits are directly tied to survival and quality of life, representing a highly compelling incentive for data sharing.

Conversely, the risk side of the calculus involves several layers of vulnerability [11]. First, there are technological risks, such as data interception during wireless transmission, database leaks, and unauthorized access by malicious actors. Second, there are institutional risks, characterized by the potential for healthcare organizations or third-party device manufacturers to monetize patient data, share it with secondary entities without explicit consent, or utilize it in ways that deviate from the primary care context. Third, there are societal and economic risks, most notably the threat of genetic or health-status discrimination by employers and insurance providers, which could lead to loss of livelihood or denial of affordable coverage.

Privacy calculus in health informatics is further complicated by the concept of institutional trust. Trust in the receiving organization acts as a powerful cognitive heuristic that reduces perceived risk. When patients maintain high levels of trust in their healthcare providers, research institutions, and the state-level regulatory bodies that oversee data protection, they perceive the risks of data sharing to be significantly lower, thereby tilting the calculus scale in favor of disclosure. However, this trust is not uniform across society and is deeply influenced by historical and structural factors, leading directly to considerations of health equity.

2.3 Health Equity and Digital Divide in Monitoring Systems

While digital health technologies offer immense potential for clinical optimization, their distribution, implementation, and subsequent social impacts are heavily mediated by existing social determinants of health. The concept of health equity requires that every individual has a fair and just opportunity to attain their highest level of health, which necessitates addressing systemic obstacles such as poverty, discrimination, and lack of access to quality healthcare. In the digital era, this mandate extends to digital health equity, ensuring that technological advancements do not inadvertently widen the health outcome gap between privileged and marginalized populations [12].

The digital divide manifests in several distinct phases of wearable technology integration. The first phase relates to physical access: high-quality, clinically validated wearable devices and the robust telecommunications infrastructure required to support them are often expensive and unevenly distributed. Low-income patients are less likely to own advanced smartphones, maintain stable high-speed internet connections, or possess the financial means to purchase wearable sensors, which are frequently not covered by public insurance schemes. The second phase involves digital health literacy: interpreting continuous data streams, troubleshooting connectivity issues, and acting on device alerts require a cognitive and technical competence that is disproportionately lower among elderly, low-income, and less-educated patient populations.

Beyond access and literacy, the third phase of the digital divide concerns algorithmic equity. The machine learning algorithms that analyze wearable telemetry to predict clinical events are typically trained on historical health datasets. Because affluent and majority populations are overrepresented in these datasets, the resulting models may exhibit significant demographic bias, showing lower predictive accuracy and higher false-positive rates when applied to minority groups. If clinical decision-making is guided by these biased algorithms, marginalized patient groups may receive suboptimal care.

To combat these disparities, healthcare institutions and public health agencies are increasingly implementing equity monitoring frameworks [13]. These frameworks involve systematic audits of digital health deployment, aiming to verify that wearable devices are distributed equitably, that algorithmic predictions are fair across diverse subgroups, and that data-driven clinical protocols do not systematically disadvantage vulnerable cohorts. Understanding how the integration of equity monitoring influences patient perceptions of systemic fairness and personal privacy represents a critical, yet understudied, dimension of contemporary medical sociology.

3. Methodology and Research Design

3.1 Research Model and Hypotheses

To investigate the structural relationships between privacy concerns, equity monitoring, and wearable data-sharing intentions among chronic illness patients, we developed an integrated theoretical model. This model builds upon the foundational privacy calculus framework by explicitly incorporating variables representing perceived data equity, institutional trust, and the perceived efficacy of equity monitoring.

The structural model is conceptualized in Figure 1.



Figure 1: Conceptual Framework of Wearable Data Sharing and Equity Monitoring

The core relationships within our conceptual framework are formalized through the following research hypotheses:

Hypothesis 1: Perceived health benefits of wearable data sharing positively influence a patient's intention to share wearable data with healthcare providers.

Hypothesis 2: Perceived privacy risks of wearable data sharing negatively influence a patient's intention to share wearable data with healthcare providers.

Hypothesis 3: Trust in healthcare institutions positively influences perceived health benefits and negatively influences perceived privacy risks.

Hypothesis 4: Perceived data equity in digital health delivery positively influences trust in healthcare institutions and negatively reduces overall privacy concerns.

Hypothesis 5: The active presence of equity monitoring mechanisms moderates the relationship between perceived privacy risks and data-sharing intentions, such that the negative impact of privacy risks is mitigated when patients perceive equity monitoring to be highly effective.

3.2 Data Collection and Sample Demographics

To test the proposed conceptual framework, we designed and executed a cross-sectional, survey-based empirical study. The target population consisted of adult patients diagnosed with at least one major chronic illness who were currently utilizing, or had been prescribed, wearable health-monitoring devices as part of their clinical care plan. Participants were recruited over a six-month period through a combination of outpatient clinic networks, chronic disease support associations, and verified online patient communities specializing in diabetes, cardiology, and respiratory care.

To ensure ethical compliance, the study protocol was reviewed and approved by the Institutional Review Board. All participants provided written or electronic informed consent prior to initiating the survey. To minimize common method bias, the survey instruments were carefully structured, utilizing reverse-coded items where appropriate, separating independent and dependent variable blocks, and ensuring participant anonymity. Out of 650 distributed questionnaires, a total of 512 completed and valid responses were obtained, yielding a usable response rate of 78.8 percent.

The demographic characteristics of the final study sample are presented in Table 1.

Table 1: Demographic Characteristics of the Study Sample

Demographic Variable	Category	Frequency	Percentage
Age	18 to 34 years	84	16.4
Age	35 to 54 years	156	30.5
Age	55 to 74 years	198	38.7
Age	75 years and older	74	14.4
Income Level	Low	142	27.7
Income Level	Medium	248	48.4
Income Level	High	122	23.9
Primary Chronic Condition	Diabetes	188	36.7
Primary Chronic Condition	Cardiovascular Diseases	164	32.0
Primary Chronic Condition	Chronic Respiratory Diseases	96	18.8
Primary Chronic Condition	Other Chronic Conditions	64	12.5
Education Level	High School or Less	118	23.0
Education Level	Some College or Vocational	174	34.0
Education Level	Bachelor Degree	154	30.1
Education Level	Postgraduate Degree	66	12.9

The sample distribution reflects a diverse representation of chronic illness patients across age cohorts, socioeconomic levels, and educational backgrounds, providing a robust empirical foundation for analyzing the socio-structural dynamics of digital health equity.

3.3 Variable Measurement and Analysis Techniques

All constructs in the research model were measured using multi-item Likert scales adapted from validated instruments in the fields of management information systems, medical sociology, and health informatics. Each item was assessed on a five-point scale, ranging from one (strongly disagree) to five (strongly agree).

The construct of perceived health benefits was assessed using four items adapted from previous health information technology adoption studies, focusing on perceived improvements in self-management, diagnosis accuracy, and peace of mind [14]. Perceived privacy risks were measured using five items addressing data breaches, unauthorized commercial secondary use, and potential health insurance discrimination. Trust in healthcare institutions was operationalized through four items measuring competence, benevolence, and integrity regarding patient data stewardship.

To capture the equity-related dimensions, we developed and validated new scales. Perceived data equity was measured using four items focusing on the fairness of wearable technology distribution, accessibility of data-driven care, and the minimization of algorithmic bias. Equity monitoring was assessed using four items capturing the extent to which independent audits, equity metrics tracking, and regulatory accountability are perceived to be active and effective in the patient's healthcare ecosystem. The dependent variable, wearable data sharing intention, was measured using three items capturing the participant's willingness to share comprehensive wearable data with their primary medical teams, clinical researchers, and public health tracking databases.

Statistical analysis was conducted using a two-stage structural equation modeling (SEM) approach [15]. First, we evaluated the measurement model using confirmatory factor analysis (CFA) to verify the reliability, convergent validity, and discriminant validity of our latent constructs. Second, we performed structural path analysis to test the hypothesized relationships and evaluate the moderating effects of equity monitoring.

Reliability was assessed using Cronbach's alpha and composite reliability (CR), with both metrics exceeding the recommended threshold of 0.70 for all constructs. Convergent validity was established as all item loadings were statistically significant and exceeded 0.70, and the Average Variance Extracted (AVE) for each construct was greater than the standard cut-off of 0.50. Discriminant validity was confirmed using the Fornell-Larcker criterion, which demonstrates that the square root of the AVE for each construct is greater than its correlation with any other construct in the model.

4. Empirical Results and Analysis

4.1 Quantitative Analysis of Privacy Concerns

The structural analysis initiated with an assessment of the overall prevalence and intensity of privacy concerns within our sample of chronic illness patients. The mean scores for the individual items comprising the perceived privacy risk scale revealed high levels of apprehension regarding data security and secondary utilization. Specifically, the risk of data being shared with commercial entities without explicit permission registered the highest mean concern, followed closely by the fear that insurance companies might utilize wearable telemetry to justify premium increases or deny coverage for specific medical procedures.

To understand the socio-demographic variations in privacy concerns, we conducted a series of independent sample t-tests and one-way analysis of variance (ANOVA) tests. The results demonstrated that privacy concerns are not uniformly distributed across the chronic illness population. Patients managing multiple co-morbidities reported significantly higher privacy concerns than those managing a single chronic condition [16]. This disparity is likely driven by the increased volume and sensitivity of the physiological data generated when tracking multiple, complex pathologies.

Furthermore, a significant relationship was identified between income levels and privacy concerns. Lower-income patients exhibited higher baseline levels of privacy concern, particularly regarding the potential for medical discrimination and financial penalties. Conversely, higher-income cohorts reported moderate privacy concerns that were more focused on technological security and hacker intrusion rather than systemic institutional discrimination. This variance underscores the necessity of analyzing digital privacy through an equity lens, acknowledging that the material consequences of a privacy breach are disproportionately more severe for economically vulnerable populations.

4.2 Equity Monitoring and Disparate Impact Evaluation

The core contribution of this research lies in demonstrating how systemic equity perceptions and the implementation of active equity monitoring frameworks influence patient privacy anxieties. To evaluate these dynamics, we examined the relationship between perceived data equity, institutional trust, and privacy concerns. The structural path coefficients derived from our model indicate a strong, positive relationship between perceived data equity and trust in healthcare institutions. When patients believe that digital health technologies are deployed fairly and that care systems strive to minimize demographic bias, their trust in those institutions increases significantly.

Importantly, our empirical findings confirm that trust acts as an essential buffer against privacy concerns [17]. Patients who report high levels of trust in their medical providers and health systems exhibit significantly lower perceived privacy risks. This trust-building mechanism is critical: it suggests that privacy concerns are not merely technical challenges to be solved with better encryption or data masking, but are deeply relational issues tied to institutional integrity and systemic fairness.

Moreover, our analysis explored whether the active presence of equity monitoring could mitigate the negative impact of privacy concerns on data-sharing intentions. In environments where patients perceived that healthcare institutions actively monitored equity metrics, audited algorithms for bias, and worked to ensure equal access to digital care, the negative relationship between privacy concerns and data-sharing willingness was significantly weakened [18]. This indicates that when a patient knows that robust, equity-focused oversight is in place, they are more willing to share their sensitive personal data, even in the presence of latent privacy concerns. Equity monitoring, therefore, functions as a powerful mechanism for securing public trust and encouraging participation in collaborative digital health ecosystems.

The results of our structural hypothesis testing are summarized in Table 2.

Table 2: Structural Model Hypothesis Testing Results

Hypothesis	Path Relation	Path Coefficient	t-Value	p-Value	Decision
Hypothesis 1	Perceived Health Benefits to Data Sharing Intention	0.42	8.84	Less than 0.001	Supported
Hypothesis 2	Perceived Privacy Risks to Data Sharing Intention	-0.28	-5.12	Less than 0.001	Supported
Hypothesis 3a	Trust in Institutions to Perceived Health Benefits	0.35	6.92	Less than 0.001	Supported
Hypothesis 3b	Trust in Institutions to Perceived Privacy Risks	-0.44	-9.05	Less than 0.001	Supported
Hypothesis 4a	Perceived Data Equity to Trust in Institutions	0.48	10.12	Less than 0.001	Supported
Hypothesis 4b	Perceived Data Equity to Perceived Privacy Risks	-0.18	-3.45	Less than 0.001	Supported
Hypothesis 5	Moderating Effect of Equity Monitoring	0.15	3.12	Less than 0.01	Supported

All five primary hypotheses were strongly supported by the empirical data. The model demonstrated high explanatory power, accounting for a substantial proportion of the variance in patients' intentions to share wearable health data.

4.3 Structural Equation Modeling Outcomes

The structural equation model fit indices were evaluated against established standards to ensure the validity of the structural paths and the robustness of the statistical conclusions. The absolute fit indices, including the ratio of chi-square to degrees of freedom, the Root Mean Square Error of

Approximation (RMSEA), and the Standardized Root Mean Square Residual (SRMR), all fell within the recommended ranges. Additionally, incremental fit indices, such as the Comparative Fit Index (CFI) and the Tucker-Lewis Index (TLI), exceeded 0.95, indicating an excellent fit between the theoretical model and the empirical data [19].

The path diagram illustrating the standardized regression coefficients, significance levels, and moderating interactions is displayed in Figure 2.



Figure 2: Structural Path Coefficients and Moderating Effects

The decomposition of effects in the structural model reveals that trust in healthcare institutions has the strongest total effect on wearable data-sharing intentions, operating both directly and indirectly through the mitigation of perceived privacy risks and the enhancement of perceived health benefits. Perceived data equity exerts a powerful indirect effect on sharing intentions, mediated through its positive impact on institutional trust.

Crucially, the statistical verification of the interaction term between perceived privacy risks and equity monitoring confirms our moderation hypothesis. To further understand this interaction, a simple slopes analysis was performed. This analysis demonstrated that for patients who perceived low levels of equity monitoring in their healthcare system, the negative relationship between privacy concerns and sharing intentions was steep and highly significant. However, for patients who perceived high levels of active equity monitoring, this negative slope was dramatically flattened and became statistically non-significant. This finding provides empirical proof that robust equity monitoring frameworks can successfully insulate data-sharing behaviors from the dampening effects of privacy apprehensions.

5. Discussion and Practical Implications

5.1 Privacy-Equity Trade-offs in Chronic Care

The empirical results of this study elucidate a critical social dynamic: the privacy decisions of chronic illness patients are deeply intertwined with their perceptions of systemic fairness and institutional equity. By integrating the structural dimensions of health equity and equity monitoring into the classical privacy calculus framework, our model offers a more comprehensive and socially realistic explanation of how patient populations navigate the trade-offs of the digital health revolution.

For chronic illness patients, the choice to share wearable data is rarely a simple calculation of individual utility. Because chronic conditions often require lifelong management, patients are highly dependent on healthcare institutions for ongoing care, making them particularly vulnerable to institutional power dynamics and systemic inequalities. Our findings demonstrate that when patients perceive that a digital health ecosystem is equitable, they are far more willing to tolerate the inherent privacy risks of continuous monitoring [20]. This suggests that privacy concerns are not just technical or legal anxieties about data security; they are manifestations of a deeper concern regarding social justice and institutional accountability.

This finding challenges the prevailing corporate and clinical paradigm, which often treats patient privacy concerns as obstacles to be overcome through consumer agreements, technical obfuscation, or paternalistic medical reassurance. Instead, our study shows that building public trust and encouraging data sharing requires a committed, systemic focus on equity. If a patient believes that the algorithm analyzing their cardiovascular telemetry was trained on a biased sample that ignores their demographic subgroup, or if they observe that lower-income members of their community are locked out of advanced monitoring technologies due to systemic cost barriers, their trust in the clinical apparatus collapses. This collapse in trust amplifies their perceived privacy risks, leading to a refusal to share data and further exacerbating the digital divide.

Consequently, a genuine resolution to the health privacy crisis must involve a commitment to digital health equity. Healthcare organizations cannot expect to secure comprehensive, high-quality patient data unless they demonstrate that they are utilizing that data to build a fairer, more accessible, and more just clinical delivery system. The privacy calculus, in essence, is a social contract: patients trade the intimacy of their physiological lives for the promise of fair, competent, and equitable medical care.

5.2 Policy and Design Recommendations

The structural insights generated by this research yield several concrete, actionable recommendations for clinical policymakers, medical device manufacturers, and software developers aiming to design inclusive, secure, and equitable digital health solutions.

First, medical device manufacturers and software developers must prioritize the implementation of Privacy-by-Design and Equity-by-Design methodologies from the earliest phases of technology development. This requires moving beyond standard security protocols to actively building systems that empower patients with granular, transparent control over their data streams. Wearable platforms should feature highly intuitive, accessible user interfaces that explain, in plain language, what data are being collected, who will access them, and how they will be used to optimize care. Rather than presenting patients with all-or-nothing data sharing agreements, systems should allow patients to select which telemetry channels they wish to share, and with whom, without fearing clinical exclusion or lower-quality care if they choose to restrict certain data flows.

Second, healthcare organizations must establish formal, transparent equity monitoring frameworks to audit the deployment and analytical processing of wearable data [21]. These frameworks should include independent, interdisciplinary oversight boards tasked with monitoring the distribution of wearable devices across different socioeconomic groups, auditing clinical algorithms for demographic and racial bias, and ensuring that data-driven protocols do not systematically disadvantage vulnerable cohorts. Importantly, the existence, operations, and findings of these equity audits must be communicated clearly to the patient community. Demonstrating a proactive, institutional commitment to fair auditing serves as a powerful trust-building mechanism that directly mitigates patient privacy concerns.

Third, public health agencies and federal regulators should design robust, equity-focused policy frameworks that protect patients from health-status and economic discrimination. Existing legislation, such as the Health Insurance Portability and Accountability Act (HIPAA) and the Genetic Information Nondiscrimination Act (GINA), should be modernized to explicitly address the unique vulnerabilities of continuous, commercial-grade wearable data. Regulatory bodies must establish strict boundaries preventing commercial insurers and employers from accessing or utilizing consumer-grade wearable telemetry for underwriting, premium adjustments, or employment decisions. By enacting legal barriers against these highly feared forms of economic discrimination, policymakers can systematically lower the perceived societal risks of health data sharing, thereby encouraging broader participation in clinical monitoring programs.

5.3 Limitations and Directions for Future Inquiry

While this study offers valuable theoretical and practical insights, several limitations must be acknowledged, which also point toward fruitful avenues for future academic inquiry.

First, this study utilized a cross-sectional survey design, which, while useful for establishing structural correlations, limits our ability to make definitive causal inferences. Future research should employ longitudinal research designs to track how patient privacy concerns and data-sharing behaviors evolve over time, particularly as patients become more familiar with wearable technologies and as equity monitoring frameworks are progressively introduced into their clinical environments.

Second, our sample, while demographically diverse, was drawn primarily from a single national healthcare context. The dynamics of institutional trust, privacy concerns, and health equity are highly dependent on the structural characteristics of a nation's healthcare system. For example, patients navigating a heavily privatized, market-driven healthcare system may report different privacy anxieties and equity concerns than those operating within a single-payer, universal public health system. Comparative cross-national studies are therefore needed to evaluate how varying healthcare delivery models and regulatory frameworks shape the relationships identified in our model.

Third, future research should explore the specific technical and design characteristics of wearable systems that best operationalize equity and privacy. Experimental research designs could test how different user interface layouts, algorithmic transparency disclosures, and data control settings impact patients' cognitive evaluations of risk, trust, and fairness. Additionally, qualitative, ethnographic inquiries could provide a deeper understanding of the lived experiences of marginalized chronic illness groups, revealing the unique socio-cultural factors that shape their interactions with digital health monitoring and clinical data sharing. By continuing to explore these critical intersections, the health informatics community can ensure that the digital health revolution is guided by the core values of security, trust, and social justice.

References

1. Martischang, R.; Nikolaou, A.; Daali, Y.; Samer, C.F.; Terrier, J. Guidance on Selecting Optimal Steady-State Tacrolimus Concentrations for Continuous IV Perfusion: Insights from Physiologically Based Pharmacokinetic Modeling. Pharmaceuticals 2024, 17, 1047.

2. Tucker, G.T. Personalized Drug Dosage—Closing the Loop. Pharm. Res. 2017, 34, 1539–1543.

3. Li, Y.; Sun, H.; Zhang, Z. The Evolution and Future Directions of PBPK Modeling in FDA Regulatory Review. Pharmaceutics 2025, 17, 1413.

4. Mostafa, S.; Polasek, T.M.; Bousman, C.; Rostami-Hodjegan, A.; Sheffield, L.J.; Everall, I.; Pantelis, C.; Kirkpatrick, C.M.J. Delineating gene-environment effects using virtual twins of patients treated with clozapine. CPT Pharmacomet. Syst. Pharmacol. 2023, 12, 168–179.

5. Gaspar, F.; Terrier, J.; Jacot-Descombes, C.; Gosselin, P.; Ardoino, V.; Lenoir, C.; Rollason, V.; Csajka, C.; Samer, C.F.; Fontana, P.; et al. Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban. Br. J. Clin. Pharmacol. 2025, 91, 2057–2069.

6. Mostafa, S.; Rafizadeh, R.; Polasek, T.M.; Bousman, C.A.; Rostami-Hodjegan, A.; Stowe, R.; Carrion, P.; Sheffield, L.J.; Kirkpatrick, C.M.J. Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia. CPT Pharmacomet. Syst. Pharmacol. 2024, 13, 424–436.

7. Chou, P.; Shannar, A.; Pan, Y.; Dave, P.D.; Xu, J.; Kong, A.-N.T. Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Drug Development and in Dietary Phytochemicals. Curr. Pharmacol. Rep. 2025, 11, 45.

8. Murad, N.; Pasikanti, K.K.; Madej, B.D.; Minnich, A.; McComas, J.M.; Crouch, S.; Polli, J.W.; Weber, A.D. Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds. Drug Metab. Dispos. 2021, 49, 169–178.

9. Garcia-Perez, M.A. Thou Shalt Not Bear False Witness Against Null Hypothesis Significance Testing. Educ. Psychol. Meas. 2017, 77, 631–662.

10. Johnstone, D.J. Tests of Significance in Theory and Practice. J. R. Stat. Soc. Ser. D (Stat.) 1986, 35, 491–498.

11. Gelman, A.; Loken, E. The Garden of Forking Paths: Why Multiple Comparisons Can Be a Problem, Even When There Is No “Fishing Expedition” or “p-Hacking” and the Research Hypothesis was Posited Ahead of Time; Department of Statistics, Columbia University: New York, NY, USA, 2013.

12. Manallack, D.T. The pK(a) Distribution of Drugs: Application to Drug Discovery. Perspect. Medicin. Chem. 2007, 1, 25–38.

13. Garcia, L.P. Mechanistic Based Pharmacokinetic-Pharmacodynamics Models for Drug Interactions and Disease Population Predictions; Acta Universitatis Upsaliensis: Uppsala, Sweden, 2023.

14. Perezgonzalez, J.D. Fisher, Neyman-Pearson or NHST? A tutorial for teaching data testing. Front. Psychol. 2015, 6, 223. [Central]

15. Rozeboom, W.W. The fallacy of the null-hypothesis significance test. Psychol. Bull. 1960, 57, 416–428.

16. Gao, J. P-values—A chronic conundrum. BMC Med. Res. Methodol. 2020, 20, 167.

17. Geddes, D.T. Inside the Lactating Breast: The Latest Anatomy Research. J. Midwifery Womens Health 2007, 52, 556–563.

18. Szucs, D.; Ioannidis, J.P.A. When Null Hypothesis Significance Testing Is Unsuitable for Research: A Reassessment. Front. Hum. Neurosci. 2017, 11, 390. [Central]

19. Amrhein, V.; Greenland, S.; McShane, B. Scientists rise up against statistical significance. Nature 2019, 567, 305–307.

20. Trabilsy, M.; Haider, S.A.; Borna, S.; Gomez-Cabello, C.A.; Genovese, A.; Prabha, S.; Forte, A.J.; Rinker, B.D.; Ho, O.A.; Elegbede, A.I. Exploring Breast Implant Illness and Its Comorbid Conditions: A Systematic Review & Meta-Analysis. J. Plast. Reconstr. Aesthet. Surg. 2025, 105, 41–54.

21. Mansoor, A.; Mahabadi, N. Volume of Distribution. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2025.